11 Apr. 2019
EUROPE-WIDE MISSION
Founding members are today delighted to announce the launch of a Europe-wide mission, across antimicrobial research and development strategies, aimed...
11 Apr. 2019
SOCIAL ENTREPRENEURSHIP INITIATIVE AND FOUNDATION
BioVersys becomes the first company to receive the seif label (Social Entrepreneurship Initiative and Foundation) for Impact Investment ReadinessVideo...
11 Apr. 2019
NZZ - EIN SCHULTERSCHLUSS GEGEN DEN 'SUPERBAZILLUS'
BioVersys featured in the Neue Zuercher Zeitung - 'Kampf gegen Antibiotika-Resistenzen'
11 Apr. 2019
BIOVERSYS AND UNIVERSITÉ DE LILLE
BioVersys and Université de Lille achieve first milestone in tuberculosis collaboration with GlaxoSmithKline Première étape franchie dans la collabor...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
